Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.59 |
| ▸ | ERN1 | O75460 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | TTK | P33981 | 8/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.50 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16911398 | 0.87 | PDGFRB (0.49) | FYNERN1PLAUTTKLRRK2 | |
| SCHEMBL15889905 | 0.87 | ERN1 (0.51) | FYNERN1TTKLRRK2CCNA2 | |
| SCHEMBL13354891 | 0.85 | TTK (0.53) | FYNERN1TTKLRRK2CCNA2 | |
| SCHEMBL12492042 | 0.85 | ALDH1A1 (0.62) | FYNERN1PLAUTTKLRRK2 | |
| SCHEMBL26833391 | 0.85 | ERN1 (0.47) | FYNERN1PLAUTTKLRRK2 | |
| SCHEMBL16911390 | 0.85 | LRRK2 (0.53) | FYNERN1PLAUTTKLRRK2 | |
| SCHEMBL26123734 | 0.85 | PIK3CD (0.49) | FYNERN1PLAUTTKLRRK2 | |
| SCHEMBL15889368 | 0.83 | LRRK2 (0.48) | FYNERN1PLAUTTKLRRK2 | |
| SCHEMBL22641671 | 0.83 | TTK (0.48) | FYNERN1TTKLRRK2CCNA2 | |
| SCHEMBL24731504 | 0.83 | PLAU (0.46) | FYNERN1PLAUTTKLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318735-B2 | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MAPK15, CDK15, MAP3K15 | FYN 143/4885ERN1 2762/4885PLAU 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.